AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32422597
Drug: Fitness tracker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fitness tracker with daily step target for 6 weeks
Trial: 33959920
Drug: Opioid pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid pain medication
Trial: 33959920
Drug: Non-opioid pain
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-opioid pain medication
Trial: 32762505
Drug: Apple vinegar
RxNorm normalized name: apple cider vinegar
DrugBank: Apple cider vinegar (DB16596)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple vinegar (AV) - 10 ml diluted in 200 ml drinking water with breakfast and dinner for 12 weeks
Trial: 34503428
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids supplementation (oral, based on children's weight for three consecutive days)
Trial: 34503428
Drug: Standard antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibiotic treatment only
Trial: 32131885
Drug: Daily use
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily use of lipid-rich emollient
Trial: 34708705
Drug: Paracetamol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol + Diclofenac
Trial: 36410494
Drug: Nebulized TA
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized TA (500 mg tid)
Trial: 36410494
Drug: IV TA
RxNorm normalized name: Liquid IV Tangerine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV TA (500 mg tid)
Trial: 35572853
Drug: LT4 treatment
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LT4 treatment
Trial: 35416437
Drug: Qingjin Yiqi
RxNorm normalized name: SILICON DIOXIDE 14 g in 100 g / .ALPHA.-TOCOPHEROL ACETATE 0.1 g in 100 g / SODIUM PYROPHOSPHATE 0.5 g in 100 g DENTAL PASTE, DENTIFRICE [Mastikis Qingjie Shine Mastic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingjin Yiqi granules (QJYQ) combined with standard rehabilitation treatments (SRTs)
Trial: 32157434
Drug: Peritonsillar infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritonsillar infiltration of tramadol (2 mg/kg)
Trial: 32157434
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 mL of peritonsillar saline)
Trial: 34518459
Drug: Donepezil 23
RxNorm normalized name: donepezil 23 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 23 mg with/without dose titration (10 mg/day escalated to 23 mg)
Trial: 34518459
Drug: No dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No dose titration
Trial: 34518459
Drug: Dose titration
RxNorm normalized name: Rebif Rebidose Titration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose titration
Trial: 36716781
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol (1 g)
Trial: 32757324
Drug: Selective retina
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective retina therapy (SRT) with a wavelength of 527 nm
Trial: 33180985
Drug: Preventive treatment
RxNorm normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive treatment with vigabatrin
Trial: 33180985
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with vigabatrin
Trial: 34548243
Drug: Camelina sativa
RxNorm normalized name: CAMELINA SATIVA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camelina sativa oil (CSO) providing 10 g/d ALA
Trial: 32419304
Drug: PF-06651600 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06651600 (200 mg once daily)
Trial: 33234648
Drug: Dexmedetomidine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.1 μg/kg/hour continuous infusion starting on the day of operation until 08:00 on postoperative day 1)
Trial: 32665034
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline administered at the same rate as dexmedetomidine)
Trial: 32404126
Drug: Solution Focused
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution Focused Brief Therapy (SFBT)
Trial: 35361442
Drug: Placebo (olive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (olive oil 1.6 g daily)
Trial: 35101083
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) 1 g intravenous bolus at the start and at the end of surgery
Trial: 33543867
Drug: Sugammadex as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex as primary reversal agent
Trial: 34267349
Drug: I-P-R-F vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-P-R-F vaccine
Trial: 33009815
Drug: 6.8 mg
RxNorm normalized name: menthol 6.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.8 mg Neuropeptide Y (NPY)
Trial: 33980168
Drug: Weekly befriending
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly befriending for 4 months from a trained volunteer
Trial: 32140672
Drug: MD1003 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MD1003 (300 mg/day)
Trial: 33908635
Drug: Riluzole, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole, a benzothiazole sodium channel blocker, dosage and duration not specified.
Trial: 32708292
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (Dabigatran, Rivaroxaban, Apixaban, Warfarin)
Trial: 32708292
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors (PPIs) use
Trial: 33720350
Drug: Tedizolid phosphate
RxNorm normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tedizolid phosphate 200 mg once daily for 7 days
Trial: 33720350
Drug: Linezolid 600
RxNorm normalized name: linezolid 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid 600 mg every 12 hours for 10 days
Trial: 33225399
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment (Lactobacillus casei Zhang, Lactobacillus plantarum P‐8, and Bifdobacterium animalis subsp. lactis V9) for 28 days
Trial: 37787888
Drug: Basal-bolus insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal-bolus insulin regimen
Trial: 32917410
Drug: Cemiplimab 3
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab 3 mg/kg intravenously every 2 weeks for 48 weeks (monotherapy cohort)
Trial: 32917410
Drug: Cemiplimab 3
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab 3 mg/kg intravenously every 2 weeks for 48 weeks with hypofractionated radiation therapy (hfRT) during week 2 (combination cohort)
Trial: 32996444
Drug: Antibiotic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic administration
Trial: 35675940
Drug: Bupivacaine injection
RxNorm normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine injection after PRF ablation
Trial: 35675940
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline injection after PRF ablation
Trial: 35337692
Drug: Control (chemotherapy)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (chemotherapy)
Trial: 38648814
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid
Trial: 33991341
Drug: Risankizumab 150
RxNorm normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 150 mg (weeks 0, 4, and 16)
Trial: 33991341
Drug: Fumaric acid
RxNorm normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fumaric acid esters (FAEs) (30 mg daily up to 720 mg daily)
Trial: 32086016
Drug: Control compounds
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control compounds (existing shared latrines)
Trial: 32086016
Drug: Intervention compounds
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention compounds (hygienic emptying)
Trial: 32985280
Drug: Probiotics (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (500 mg daily for 10 weeks)
Trial: 32985280
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for 10 weeks)
Trial: 32926760
Drug: Concurrent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent treatment (RT delivered on the same day as or in between doses of ICT)
Trial: 32926760
Drug: Nonconcurrent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonconcurrent treatment (RT not delivered on the same day as ICT)
Trial: 33859685
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion (0.4 mg/kg continuous infusion over 20 min)
Trial: 33744981
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of bevacizumab (IVB)
Trial: 32432388
Drug: Lorecivivint 0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorecivivint 0.07 mg
Trial: 32432388
Drug: Lorecivivint 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorecivivint 0.03 mg
Trial: 32432388
Drug: Lorecivivint 0.23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorecivivint 0.23 mg
Trial: 33847018
Drug: L‐PRF
RxNorm normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐PRF
Trial: 36386125
Drug: Xinbao pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinbao pill (XBP)
Trial: 36386125
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug therapy combined with placebo
Trial: 34959963
Drug: Goji berries
RxNorm normalized name: GOJI BERRY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goji berries (28 g, five times weekly for 90 days)
Trial: 34959963
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (supplement containing 6 mg L and 4 mg Z, five times weekly for 90 days)
Trial: 33983449
Drug: Intradialytic cycling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradialytic cycling (IDC) - 6-month programme, thrice weekly, moderate intensity cycling (RPE 12-14)
Trial: 35224215
Drug: Vaginal washing
RxNorm normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal washing with 20 cc of normal saline 0.9% before Misoprostol insertion
Trial: 33176826
Drug: Encapsulated natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated natural mushroom-derived vitamin D2 (25 μg or 1000 IU)
Trial: 33176826
Drug: Matched-dose encapsulated
RxNorm normalized name: poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched-dose encapsulated vitamin D3 (25 μg or 1000 IU)
Trial: 35288397
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg empagliflozin for 14 days
Trial: 35597230
Drug: Higher anthocyanin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher anthocyanin intake (>10 mg/d)
Trial: 35597230
Drug: Lower anthocyanin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower anthocyanin intake (<10 mg/d)
Trial: 32895971
Drug: Enteral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteral erythromycin estolate (250 mg) + Intravenous metoclopramide (10 mg every 6-8 hours)
Trial: 32895971
Drug: Intravenous metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoclopramide (10 mg every 6-8 hours) + Placebo (every 6 hours for 7 days)
Trial: 32032916
Drug: Ondansetron 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.2 mg.kg‐1
Trial: 32032916
Drug: Dexamethasone 0.1
RxNorm normalized name: dexamethasone 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.1 mg.kg‐1
Trial: 36241872
Drug: ivabradine (5-7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine (5-7.5 mg)
Trial: 39705390
Drug: Clopidogrel-aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel-aspirin
Trial: 35373583
Drug: Dual Antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual Antiplatelet Therapy (aspirin plus clopidogrel)
Trial: 34768338
Drug: Fixed-dose oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose oxygen treatment
Trial: 32951712
Drug: Vacuum myofascial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum myofascial therapy device (VT)
Trial: 32951712
Drug: Comparison physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison physical therapy program (PTP)
Trial: 34872625
Drug: Integrated cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated cognitive-behavioral therapy (CBT) for ED-PTSD
Trial: 32769842
Drug: Lotrafilcon B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotrafilcon B lenses packaged in and cared for with EOBO-containing solutions (CLEAR CARE PLUS with HydraGlyde or OPTI-FREE PUREMOIST)
Trial: 36397223
Drug: Five-element music
RxNorm normalized name: HISTA-FIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-element music therapy, 30 min each session, once every two days, 3 treatments a week for 4 weeks.
Trial: 36397223
Drug: Five-element music
RxNorm normalized name: HISTA-FIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-element music therapy.
Trial: 36129521
Drug: Azithromycin (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (n = 13, standard dose every 10 days)
Trial: 36129521
Drug: NB‐UVB (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NB‐UVB (n = 11, thrice weekly)
Trial: 32383615
Drug: Aminophylline (5mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (5mg/kg slow intravenous injection)
Trial: 32383615
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 mL/kg of intravenous 10% solution of dextrose saline)
Trial: 34534071
Drug: 5-week adjunctive
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-week adjunctive bright light therapy with a gradual advance protocol
Trial: 35726738
Drug: Colorado Protocol
RxNorm normalized name: influenza B virus B/Colorado/06/2017 antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colorado Protocol (aspirin, steroid, and antibiotic)
Trial: 35791755
Drug: Mirikizumab 250
RxNorm normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirikizumab 250 mg Q4W
Trial: 35791755
Drug: Mirikizumab 250
RxNorm normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirikizumab 250 mg Q4W/125 mg Q8W
Trial: 35791755
Drug: Mirikizumab 250
RxNorm normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirikizumab 250 mg Q4W/250 mg Q8W
Trial: 33080034
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light treatment (10,000 lux)
Trial: 34839447
Drug: Fungal keratitis
RxNorm normalized name: miconazole nitrate Topical Cream [Anti-Fungal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fungal keratitis treatment
Trial: 35080187
Drug: Bevacizumab 2.5
RxNorm normalized name: Bevacizumab 2.5 MG/0.1 ML Intraocular Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 2.5 mg/kg d1, d8 (group A)
Trial: 35080187
Drug: Bevacizumab 5
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 5 mg/kg d1, d8 (group B)
Trial: 35080187
Drug: Bevacizumab 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 7.5 mg/kg d1, d8 (group C)
Trial: 33255704
Drug: Psychological Capital
RxNorm normalized name: Lespedeza capitata flowering top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological Capital Intervention (PCI) using a daily online self-learning approach
Trial: 616886769
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine-based nursing care
Trial: 32696031
Drug: Amoxicillin plus
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin plus metronidazole (AM+MT) combined with SD
Trial: 32581088
Drug: Rituximab (4×375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (4×375 mg/m2) and glucocorticoids (higher or lower dose regimen)
Trial: 36183042
Drug: Subtenon 20-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subtenon 20-mg triamcinolone injection (TA group)
Trial: 34699409
Drug: Vibegron 75
RxNorm normalized name: vibegron 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibegron 75 mg once daily for 28 days
Trial: 32988518
Drug: Feeding frequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Feeding frequency 3 times daily
Trial: 32988518
Drug: Feeding frequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Feeding frequency 4 times daily
Trial: 32988518
Drug: Different feeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different feeding frequencies (3 to 5 times daily)
Trial: 33449304
Drug: Capsaicinoids at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicinoids at 10 μmol/L
Trial: 33449304
Drug: Capsaicinoids preconditioning
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicinoids preconditioning at 10 μmol/L over 5 min
Trial: 33449304
Drug: Capsaicinoids at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicinoids at 50 μmol/L
Trial: 32845283
Drug: Telmisartan, 40
RxNorm normalized name: Telmisartan, 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan, 40 mg
Trial: 34197764
Drug: CoronaVac 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac 1.5 μg
Trial: 34197764
Drug: CoronaVac 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac 3.0 μg
Trial: 34197764
Drug: CoronaVac 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac 1.5 μg (phase 2)
Trial: 34197764
Drug: CoronaVac 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac 3.0 μg (phase 2)
Trial: 32920241
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of outcome- and process-based incentives
Trial: 36078584
Drug: HRV-guided training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRV-guided training (HRV-G)
Trial: 36078179
Drug: Predefined training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predefined training (PRED-G)
Trial: 36078179
Drug: Both HRV-G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both HRV-G and PRED-G
Trial: 32150232
Drug: Gabapentin up
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin up to 1200 mg/d, orally, with 9 medical management visits (20 minutes each)
Trial: 32540236
Drug: Topical treatments
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatments for actinic keratosis
Trial: 32540236
Drug: DCE (Discrete
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCE (Discrete Choice Experiment) at baseline and final post-treatment assessment
Trial: 36212173
Drug: Dexmedetomidine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.4 μg·kg‐1·h‐1 before and during anesthesia, 0.2 μg·kg‐1·h‐1 after induction)
Trial: 33114585
Drug: 35 g
RxNorm normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 g protein (MOD)
Trial: 33114585
Drug: 70 g
RxNorm normalized name: alcohol .70 g in 1 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 g protein (HIGH)
Trial: 33867179
Drug: Sucralfate (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (20 mg/kg per dose up to 1 g)